TY - JOUR
T1 - Biocompatible inorganic nanoparticles for [F-18]-fluoride binding with applications in PET imaging
AU - Jauregui-Osoro, Maite
AU - Williamson, Peter A.
AU - Glaria, Arnaud
AU - Sunassee, Kavitha
AU - Charoenphun, Putthiporn
AU - Green, Mark A.
AU - Mullen, Gregory E. D.
AU - Blower, Philip J.
PY - 2011/6/21
Y1 - 2011/6/21
N2 - A wide selection of insoluble nanoparticulate metal salts was screened for avid binding of [F-18]-fluoride. Hydroxyapatite and aluminium hydroxide nanoparticles showed particularly avid and stable binding of [F-18]-fluoride in various biological media. The in vivo behaviour of the [F-18]-labelled hydroxyapatite and aluminium hydroxide particles was determined by PET-CT imaging in mice. [F-18]-labelled hydroxyapatite was stable in circulation and when trapped in various tissues (lung embolisation, subcutaneous and intramuscular), but accumulation in liver via reticuloendothelial clearance was followed by gradual degradation and release of [F-18]-fluoride (over a period of 4 h) which accumulated in bone. [F-18]-labelled aluminium hydroxide was also cleared to liver and spleen but degraded slightly even without liver uptake (subcutanenous and intramuscular). Both materials have properties that are an attractive basis for the design of molecular targeted PET imaging agents labelled with F-18.
AB - A wide selection of insoluble nanoparticulate metal salts was screened for avid binding of [F-18]-fluoride. Hydroxyapatite and aluminium hydroxide nanoparticles showed particularly avid and stable binding of [F-18]-fluoride in various biological media. The in vivo behaviour of the [F-18]-labelled hydroxyapatite and aluminium hydroxide particles was determined by PET-CT imaging in mice. [F-18]-labelled hydroxyapatite was stable in circulation and when trapped in various tissues (lung embolisation, subcutaneous and intramuscular), but accumulation in liver via reticuloendothelial clearance was followed by gradual degradation and release of [F-18]-fluoride (over a period of 4 h) which accumulated in bone. [F-18]-labelled aluminium hydroxide was also cleared to liver and spleen but degraded slightly even without liver uptake (subcutanenous and intramuscular). Both materials have properties that are an attractive basis for the design of molecular targeted PET imaging agents labelled with F-18.
U2 - 10.1039/c0dt01618g
DO - 10.1039/c0dt01618g
M3 - Article
SN - 1477-9234
VL - 40
SP - 6226
EP - 6237
JO - DALTON TRANSACTIONS (2003)
JF - DALTON TRANSACTIONS (2003)
IS - 23
ER -